Last reviewed · How we verify
NCT03822195
Lectine Pathway in Unstable Carotid Plaque
trial testing Carotid endoarterectomy in Carotid Artery Plaque. Withdrawn.
31 January 2021
Quick facts
| Lead sponsor | Fondazione Policlinico Universitario Agostino Gemelli IRCCS |
|---|---|
| Status | Withdrawn |
| Study type | OBSERVATIONAL |
| Start date | 1 April 2019 |
| Primary completion | 31 January 2021 |
| Estimated completion | 28 February 2021 |
Drugs / interventions tested
- Carotid endoarterectomy
Conditions studied
- Carotid Artery Plaque — all drugs for Carotid Artery Plaque →
- Mannose-Binding Lectin Complement Pathway — all drugs for Mannose-Binding Lectin Complement Pathway →
Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Who can join
Adults 40 to 80, any sex, with Carotid Artery Plaque or Mannose-Binding Lectin Complement Pathway. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study is aimed to investigate the possible role of lectin pathway - an alternative pathway of complement activation - in affecting stability of carotid atherosclerotic plaques and the possible correlations with clinical neurologic features.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Precision Medicine in Neurology: The Inspirational Paradigm of Complement Therapeutics.
Gavriilaki M, Kimiskidis VK, Gavriilaki E. · · 2020 · cited 21× · PMID 33114553 · DOI 10.3390/ph13110341
Verify or expand the search:
- PubMed search for NCT03822195
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Carotid Artery Plaque
Currently open trials in the same condition.
- NCT07296965 — Oral Microbiome in Carotid Atherosclerosis · recruiting
- NCT07004673 — 18F FDG and 68Ga FAPI PET/MR Imaging of Carotid Artery Plaque Vulnerability: A Clinical Study in Carotid Artery Plaque P · recruiting
- NCT05975554 — The Effect of Low-dose Interleukin-2 on the Immune Landscape of Human Atherosclerotic Plaques at Single Cell Resolution. · NA · active not recruiting
- NCT04073797 — PET Imaging of Inflammation and Lipid Lowering Study · NA · recruiting
- NCT02360137 — Atherosclerotic Plaque Characteristics Associated With a Progression Rate of the Plaque in Carotids and a Risk of Stroke · active not recruiting
Other Fondazione Policlinico Universitario Agostino Gemelli IRCCS trials
Trials by the same sponsor.
- NCT07514572 — Impact of Estimated Weight and Height on Nutritional Assessment in Elderly · NA · not yet recruiting
- NCT07504679 — Adipose Visceral and Epicardial Risk Evaluation · NA · not yet recruiting
- NCT07520643 — MISTIC Study: Atherosclerosis, Neurocognition & Cardiovascular Signaling · not yet recruiting
- NCT07479238 — Breath Test-Based Assessment of SIBO in Chronic Pancreatitis and Partial Pancreatectomy · not yet recruiting
- NCT07494227 — Development of the SC-IBD Self-Care Measurement Scale · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03822195 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Last refreshed: 24 July 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03822195.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing